Effect of Thickened Feeds on Clinical Outcomes in Children With Brief Resolved Unexplained Event
Launched by BOSTON CHILDREN'S HOSPITAL · Jul 15, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how thickened feeds—foods or liquids that have been made thicker—can affect the health and wellbeing of infants who have experienced a Brief Resolved Unexplained Event (BRUE). A BRUE is when a baby suddenly has a scary episode, like trouble breathing or turning blue, but then quickly gets better and shows no lasting problems. The study will focus on babies less than one year old who were admitted to Boston Children’s Hospital after their first BRUE.
To participate, infants must be under one year of age and should not have any other serious health issues, like seizure disorders or certain heart conditions. The trial is currently recruiting participants, and families involved can expect to help researchers understand if thickened feeds can improve outcomes for these infants. This could potentially lead to better care for babies with similar events in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Less than 1 year of age
- • Admitted to Boston Children's Hospital after experiencing first lifetime brief resolved unexplained event.
- Exclusion Criteria:
- • Any pre-existing medical diagnoses that exclude brief resolved unexplained event diagnosis including seizure disorders and cyanotic congenital heart disease
- • Already receiving thickened liquids for treatment of another condition
About Boston Children's Hospital
Boston Children's Hospital is a leading pediatric healthcare institution renowned for its commitment to advancing child health through innovative research and exceptional clinical care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in pediatric medicine to conduct rigorous and ethically sound research studies aimed at improving treatment options and outcomes for children. With a collaborative approach that integrates cutting-edge technology and multidisciplinary teams, Boston Children's Hospital is dedicated to translating scientific discoveries into practical applications that enhance the well-being of young patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Daniel R Duncan, MD, MPH
Principal Investigator
Boston Children's Hospital
Rachel Rosen, MD, MPH
Study Director
Boston Children's Hospital
Sudarshan Jadcherla, MD
Study Director
Nationwide Children's Hospital
Taher Omari, PhD
Study Director
Flinders University
Samuel Nurko, MD, MPH
Study Director
Boston Children's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials